Biotechnology
OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF
NANJING, China, Nov. 17, 2021 /PRNewswire/ -- OncoOne
2021-11-17 22:00
1413
Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe
* The therapy aims to re-energize a patient's immune system to fight cancer
tumors
* Initial commercialization will target leading oncology centers in Germany,
France, Italy, and Spain LAKEWOOD, Colo. and SAN DIEGO, Nov. 16, 2021
/PRNewswire/ --Terumo Blood and Cell Technologies
2021-11-17 00:00
1651
FibroBiologics Secures $100 Million Capital Commitment from GEM as Company Seeks to Go Public
The Company plans to go public via SPAC, reverse merger, or a direct listing HOUSTON, Nov. 16, 2021 /PRNewswire/ -- FibroBiologics, a clinical stage company developing fibroblast-based therapeutic cures for chronic diseases, announced today that it has signed an agreement with GEM Global Y...
2021-11-16 23:07
1203
Delivering Health with Science: Huison Virgin DHA at the World Congress of Omega-3 Science & Technology
XIAMEN, China, Nov. 16, 2021 /PRNewswire/ -- The World Congress of Omega-3 Science & Technology, hosted by ISOR, was webcast worldwide onNovember 13 and November 14, 2021. It gathered 28 top experts and heads of relevant industry organizations from around the world who are deeply engaged in Omega...
2021-11-16 21:30
1293
Happiness Development Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency
NANPING, China, Nov. 16, 2021 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"),(NASDAQ: HAPP) announced today that the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") onNovember 11, 2021, no...
2021-11-16 21:00
1444
Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer
SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment ofJohn Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the developme...
2021-11-16 00:00
1869
CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA
SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted Priority M...
2021-11-15 22:10
4968
Validation Study Showcases Success of LSBD's Rapid SARS-CoV-2 Antibody Test
SYDNEY, Nov. 15, 2021 /PRNewswire/ -- The iQ Group Global Ltd (iQG Ltd) (NSX:IQG) on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), has announced the successful completion of a clinical validation study showcasing the efficacy of its rapid SARS-Cov-2 Antibody test. The results of ...
2021-11-15 22:00
1430
InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA
BEIJING, Nov. 14, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today the Investigational New Drug (IND) clearance of itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189 by the US Food and Drug A...
2021-11-15 08:30
1682
China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results
HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the financial results for the qu...
2021-11-13 05:30
4614
Tabernacle Health Group Launches Revolutionary Immunity Booster. Natural Health Supplement Avrocil (TM) Treats Cold and Flu Symptoms caused by Upper Respiratory Tract Infections
SINGAPORE, Nov. 11, 2021 /PRNewswire/ -- The pandemic sped up participation in virtual exercise classes acrossthe United States, as countless fitness enthusiasts switched to indoor workouts to avoid viruses, such as those that lead to accelerated upper respiratory tract infections, whose sympto...
2021-11-12 02:00
1738
Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting
- Lunit to present three abstracts about its AI biomarker platform Lunit SCOPE IO, also to be demonstrated during the event in booth #423 - One immunotherapy combination study adds significant evidence for the potential value of using Lunit SCOPE IO in clinical practice to predict patient res...
2021-11-11 23:00
1450
Happiness Biotech Group Limited Announces Name Change to Happiness Development Group Limited and Re-Designation of Its Ordinary Shares
NANPING, China, Nov. 11, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (" Happiness" or the "Company"), (NASDAQ: HAPP), is pleased to announce that effective onNovember 12, 2021, the Company will change its name to "Happiness Development Group Limited" (the "Name Change"). In addition, the ...
2021-11-11 21:00
1409
Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting
HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a ...
2021-11-10 17:00
1494
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC
* Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity * Both studies are undergoing phase 1 clinical trials in the United States SHANGHAI and GAITHERSBURG, Md. and SEONGNAM, South Korea, Nov. 9, 2021 /PRNewswire/ -- I-Mab ...
2021-11-09 21:05
1775
Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021
MELBOURNE, Australia, Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying vi...
2021-11-09 20:30
1438
InnoRNA of China participates in the Hanmi Science Consortium …"To join forces to eliminate 'vaccine divide'"
SEOUL, South Korea, Nov. 9, 2021 /PRNewswire/ -- Global businesses and institutes are knocking on the door to the Hanmi Science Consortium having proprietary LNP technology. After Hanmi Science concluded a 'pandemic science alliance agreement' with theUniversity of Oxford, increasingly more entit...
2021-11-09 14:20
1510
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH
BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting onDecember 11-14, 2021, which will be hold o...
2021-11-09 13:06
1812
Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery
SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd ("SK Chemicals", KRX 285...
2021-11-09 10:47
2129
BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston
BOSTON, Nov. 5, 2021 /PRNewswire/ -- South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration. BIORCHESTRA discovered a disease-associated microRNA that was found to be significantly up-regulated in samples from Alzheimer's disease patients. It then...
2021-11-08 22:59
2756
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5216
